The U.S. Food and Drug Administration (FDA) has released a critical safety communication regarding Ocaliva (obeticholic acid), a medication used to treat primary biliary cholangitis (PBC). As an organization dedicated to patient advocacy, AWKO wants to ensure that all PBC patients are informed about this important update.
Key Points from the FDA Warning
- Expanded Risk: The FDA has identified cases of serious liver injury among PBC patients taking Ocaliva who do not have cirrhosis.
- Increased Risks: In a postmarket clinical trial, patients receiving Ocaliva showed a higher risk of liver transplant and death compared to those on placebo.
- Monitoring Crucial: Frequent liver test monitoring is necessary to identify worsening liver function and ensure appropriate discontinuation of Ocaliva.
What is Primary Biliary Cholangitis (PBC)?
PBC is a chronic, progressive liver disease that primarily affects women between the ages of 35 and 70. It is characterized by:
- Inflammation and scarring of the small bile ducts in the liver
- An autoimmune reaction where the body’s immune system attacks its own tissues
- Gradual blockage of bile ducts, leading to liver damage
- Symptoms of PBC may include fatigue, itchy skin, dry eyes and mouth, and in advanced stages, jaundice.
What This Means for PBC Patients
If you are currently taking Ocaliva for PBC, it’s crucial to:
- Consult Your Doctor: Discuss these new warnings with your healthcare provider immediately.
- Be Vigilant: Watch for symptoms that may indicate worsening liver injury. Contact your doctor immediately if you experience any concerning symptoms, including:
- Swollen belly
- Yellow eyes or skin
- Bloody or black stools
- Mental status changes
- Severe or persistent belly pain, nausea, vomiting, or diarrhea
- Regular Monitoring: Expect more frequent liver function tests during Ocaliva treatment.
Ocaliva Lawsuits
AWKO will continue to monitor developments regarding Ocaliva and other PBC treatments. We remain committed to providing up-to-date, accurate information to support the PBC community.
If you or a loved one has been prescribed Ocaliva (obeticholic acid) for primary biliary cholangitis (PBC) and has experienced serious liver injury or complications, contact us today to schedule a free consultation. Our experienced attorneys are here to help you understand your legal rights and options. We are committed to advocating for patients affected by potentially dangerous medications and can help you seek the justice and compensation you may deserve.
Don’t hesitate to reach out – your health and well-being are our top priority. Call us now at (844) 794-7402 to speak with a knowledgeable member of our team about your potential Ocaliva case.